Does TAHOR Cause Interstitial lung disease? 5 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Interstitial lung disease have been filed in association with TAHOR. This represents 4.0% of all adverse event reports for TAHOR.
5
Reports of Interstitial lung disease with TAHOR
4.0%
of all TAHOR reports
2
Deaths
4
Hospitalizations
How Dangerous Is Interstitial lung disease From TAHOR?
Of the 5 reports, 2 (40.0%) resulted in death, 4 (80.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAHOR. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does TAHOR Cause?
Hepatocellular injury (11)
Rhabdomyolysis (11)
Cholestasis (9)
Renal failure (8)
Thrombocytopenia (8)
Drug reaction with eosinophilia and systemic symptoms (6)
Inflammation (6)
Lung disorder (6)
Pancytopenia (6)
Weight decreased (6)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which TAHOR Alternatives Have Lower Interstitial lung disease Risk?
TAHOR vs TALAZOPARIB
TAHOR vs TALC
TAHOR vs TALIGLUCERASE ALFA
TAHOR vs TALIMOGENE LAHERPAREPVEC
TAHOR vs TALQUETAMAB